BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing specialty pharmaceuticals for the treatment of rare and infectious diseases. The company primarily develops oral medicines that inhibit specific enzymes involved in disease processes, with a key focus on antiviral and immune modulatory therapies.
Company News
BioCryst Pharmaceuticals granted nine newly-hired employees stock options to purchase 36,700 shares and restricted stock units covering 71,400 shares of company stock, with options priced at $8.29 per share and vesting in four equal annual installments.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
BioCryst Pharmaceuticals reported record Q2 2025 revenue of $163.4 million, achieving its first significant GAAP net profit. ORLADEYO prescription drug sales grew 45% year-over-year, driving strong financial performance and positioning the company for continued growth in rare disease treatments.
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?